Deputy Minister for Women's Health Delyth Jewell stated that Wales' current endometriosis setup is unsustainable and called for a regional or national service model.

The American College of Obstetricians and Gynecologists noted that more than one in three perimenopausal and postmenopausal women report depressive symptoms

552c7ae14Claim

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

552c7ae14Claim

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

552c7ae14Claim

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

552c7ae14Claim

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

552c7ae14Claim

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

552c7ae14Claim

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

552c7ae14Claim

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

552c7ae14Claim

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

552c7ae14Claim

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

552c7ae14Claim

In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

552c7ae14Claim

Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition

552c7ae14Claim

Thyroid eye disease symptoms can include eye swelling, eyelid retraction, a constant stare, proptosis, diplopia, and pain, which can be disfiguring, debilitating, or blinding

552c7ae14Claim

Roche reported that no new safety signals were identified for satralizumab across the phase 3 SatraGO-1 and SatraGO-2 clinical trials

552c7ae14Claim

Satralizumab's phase 3 SatraGO trial program demonstrated consistent efficacy in an overall trial population that included patients with both active and chronic thyroid eye disease

552c7ae14Claim

Genentech's interleukin-6 inhibitor tocilizumab has been studied off-label as a second-line therapy for patients with moderate-to-severe, glucocorticoid-resistant thyroid eye disease

552c7ae14Claim

Satralizumab dosing requires three initial loading injections at weeks 0, 2, and 4, followed by maintenance injections every 4 weeks

552c7ae14Claim

The most common adverse events reported for satralizumab in the SatraGO-1 and SatraGO-2 clinical trials were upper respiratory tract infections and elevated alanine aminotransferase levels

Deputy Minister for Women's Health Delyth Jewell stated that Wales' current endometriosis setup is unsustainable and called for a regional or national service model.

Childhood trauma leads people to develop psychosis

More young people need to get their brain scanned

The American College of Obstetricians and Gynecologists noted that more than one in three perimenopausal and postmenopausal women report depressive symptoms

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition

Thyroid eye disease symptoms can include eye swelling, eyelid retraction, a constant stare, proptosis, diplopia, and pain, which can be disfiguring, debilitating, or blinding

Roche reported that no new safety signals were identified for satralizumab across the phase 3 SatraGO-1 and SatraGO-2 clinical trials

Satralizumab's phase 3 SatraGO trial program demonstrated consistent efficacy in an overall trial population that included patients with both active and chronic thyroid eye disease

Genentech's interleukin-6 inhibitor tocilizumab has been studied off-label as a second-line therapy for patients with moderate-to-severe, glucocorticoid-resistant thyroid eye disease

Satralizumab dosing requires three initial loading injections at weeks 0, 2, and 4, followed by maintenance injections every 4 weeks

The most common adverse events reported for satralizumab in the SatraGO-1 and SatraGO-2 clinical trials were upper respiratory tract infections and elevated alanine aminotransferase levels